{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:08:50Z","timestamp":1791446930791,"version":"4.3.3"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Heart Fail"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This prespecified analysis of the FIDELIO\u2010DKD trial compared the effects of finerenone, a selective non\u2010steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure (HF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      Patients with T2D and CKD (urine albumin\u2010to\u2010creatinine ratio\u2009\u226530\u20135000\u2009mg\/g and estimated glomerular filtration rate [eGFR] \u226525\u2013&lt;75\u2009ml\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      ), without symptomatic HF with reduced ejection fraction (New York Heart Association II\u2013IV) and treated with optimized renin\u2013angiotensin system blockade were randomized to finerenone or placebo. The composite cardiovascular (CV) outcome (CV death, non\u2010fatal myocardial infarction, non\u2010fatal stroke, or hospitalization for HF) and composite kidney outcome (kidney failure, sustained \u226540% decrease in eGFR from baseline, or renal death) were analysed by investigator\u2010reported medical history of HF. Of 5674 patients, 436 (7.7%) had a history of HF. Over a median follow\u2010up of 2.6\u2009years, the effect of finerenone compared with placebo on the composite CV outcome was consistent in patients with and without a history of HF (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.50\u20131.06 and HR 0.90, 95% CI 0.77\u20131.04, respectively; interaction\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.33). The effect of finerenone on the composite kidney outcome did not differ by history of HF (HR 0.79, 95% CI 0.52\u20131.20 and HR\u00a00.83, 95% CI 0.73\u20130.94, respectively; interaction\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.83).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In FIDELIO\u2010DKD, finerenone improved cardiorenal outcome in patients with CKD and T2D irrespective of baseline HF history.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2469","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T09:13:36Z","timestamp":1646298816000},"page":"996-1005","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the\n                    <scp>FIDELIO\u2010DKD<\/scp>\n                    trial"],"prefix":"10.1093","volume":"24","author":[{"given":"Gerasimos","family":"Filippatos","sequence":"first","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology Attikon University Hospital  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Michigan School of Medicine  Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Richard L. Roudebush VA Medical Center and Indiana University  Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"University of Cyprus Medical School  Nicosia Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[{"name":"Cardiorenal Translational Laboratory and Hypertension Unit Institute of Research imas12  Madrid Spain"},{"name":"CIBER\u2010CV, Hospital Universitario 12 de Octubre  Madrid Spain"},{"name":"Faculty of Sport Sciences European University of Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen  Gentofte Denmark"},{"name":"Department of Clinical Medicine University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology Hannover Medical School  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[{"name":"Department of Medicine Duke University School of Medicine  Durham NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[{"name":"Research and Development Preclinical Research Cardiovascular, Bayer AG  Wuppertal Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Scott","sequence":"additional","affiliation":[{"name":"Data Science and Analytics, Bayer PLC  Reading UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Joseph","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development, Bayer AG  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Chicago Medicine  Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies German Center for Cardiovascular Research Partner Site Berlin, Charit\u00e9\u00a0\u2013\u00a0Universit\u00e4tsmedizin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FIDELIO\u2010DKD Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1170"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht515"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2064"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.022"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013255"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002137"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051898"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht187"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw132"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.113"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003316"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.079"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057983"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.813"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2015.0356"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.905"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.04.086"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.05.002"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.218"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000091"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10360"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000340"},{"key":"e_1_2_7_31_1","unstructured":"ClinicalTrials.gov.Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on morbidity (Events Indicating Disease Worsening) and Mortality (Death Rate) in Participants with Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS\u2010HF).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435626. (Accessed 20 April 2021)."}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2469","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2469","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:16:26Z","timestamp":1767701786000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ejhf.2469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1002\/ejhf.2469"],"URL":"https:\/\/doi.org\/10.1002\/ejhf.2469","archive":["Portico"],"relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"2021-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}